Hypercalcemia of malignancy and new treatment options
TLDR
Treatment is aimed at lowering the serum calcium concentration by inhibiting bone resorption and increasing urinary calcium excretion, the former accomplished via bisphosphonate therapy and the latter with aggressive hydration.Abstract:
Hypercalcemia of malignancy affects up to one in five cancer patients during the course of their disease. It is associated with both liquid malignancies, commonly multiple myeloma, leukemia, and non-Hodgkins lymphoma and solid cancers, particularly breast and renal carcinomas as well as squamous cell carcinomas of any organ. The clinical manifestations of hypercalcemia are generally constitutional in nature and not specific to the inciting malignancy. Such physical manifestations can range from malaise to lethargy and confusion. Constipation and anorexia are common. Acute kidney injury is likely the most frequently encountered manifestation of end organ damage. Symptomatology is closely linked to both the absolute elevation of serum calcium levels and the rapidity of calcium rise. The majority of cases are humoral in etiology and related to parathyroid hormone-related protein (PTHrP). Approximately 20% of cases are the result of direct bone metastasis with extra-renal 1,25-dihydroxyvitamin D (calcitriol) and ectopic parathyroid hormone production likely accounting for less than 1% of cases. The diagnosis of hypercalcemia of malignancy is confirmed either by an elevated PTHrP or by an evidence of bone metastasis in the appropriate clinical setting. Treatment is predicated on the patient's symptoms and absolute serum calcium level. Interventions are aimed at lowering the serum calcium concentration by inhibiting bone resorption and increasing urinary calcium excretion, the former accomplished via bisphosphonate therapy and the latter with aggressive hydration. Novel therapies for refractory disease include denosumab, a monoclonal antibody against the receptor activator of nuclear factor κB ligand, and the calcimimetic cinacalcet. Finally, anti-PTHrP antibodies have been successfully deployed in animal models of disease. Despite the efficacy of the above therapies, hypercalcemia of malignancy portends an ominous prognosis, indicating advanced and often refractory cancer with survival on the order of months.read more
Citations
More filters
Journal ArticleDOI
The essential metals for humans: a brief overview
Maria Antonietta Zoroddu,Jan Aaseth,Guido Crisponi,Serenella Medici,Massimiliano Francesco Peana,Valeria Marina Nurchi +5 more
TL;DR: The human body needs about 20 essential elements in order to function properly and among them, for certain, 10 are metal elements, though for every metal we do need, there is another one in our body we could do without it as discussed by the authors.
Journal ArticleDOI
Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment
Ourania Nicolatou-Galitis,Morten Schiødt,Rui Amaral Mendes,Carla Ripamonti,Sally Hope,Lawrence Drudge-Coates,Daniela Niepel,Tim Van den Wyngaert +7 more
TL;DR: This review describes the incidence and pathophysiology of MRONJ, a rare, but potentially serious, adverse event associated with high cumulative doses of bisphosphonates or denosumab, and provides guidance for dental practitioners with regard to the screening, prophylactic treatment, diagnosis, and management of patients with this condition.
Journal ArticleDOI
Cancer-Related Hypercalcemia
TL;DR: The cancers associated with hypercalcemia are reviewed and their proposed mechanisms, nontumor-mediated hypercalccemia, as well as diagnosis and treatment strategies for each condition are reviewed.
Journal ArticleDOI
Breast cancer bone metastases: pathogenesis and therapeutic targets.
TL;DR: An overview of systemic therapies currently recommended for the treatment of breast cancer bone metastases and emerging therapeutic targets are provided and key pathways dysregulated in breast cancer metastasis to bone are explored.
References
More filters
Journal ArticleDOI
Mechanisms of bone metastasis.
TL;DR: Bone metastasis causes severe bone pain and can result in fractures without any injury, as well as other life-threatening conditions, and patients with prostate cancer who usually have bone metastasis that shows increased new bone formation also have increased bone destruction in the same lesions.
Journal ArticleDOI
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Robert A. Kyle,Morie A. Gertz,Thomas E. Witzig,John A. Lust,Martha Q. Lacy,Angela Dispenzieri,Rafael Fonseca,S. Vincent Rajkumar,Janice R. Offord,Dirk R. Larson,Matthew E. Plevak,Terry M. Therneau,Philip R. Greipp +12 more
TL;DR: Multivariate analysis revealed that age, plasma cell labeling index, low platelet count, serum albumin value, and the log of the creatinine value were the most important prognostic factors for newly diagnosed multiple myeloma.
Journal ArticleDOI
Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium
Abdul B. Abou-Samra,Harald Jüppner,Thomas Force,Mason W. Freeman,X F Kong,Ernestina Schipani,Pablo Ureña,Julia E. Richards,Joseph V. Bonventre,John T. Potts +9 more
TL;DR: Using expression cloning, a cDNA clone is isolated encoding rat bone PTH/PTHrP receptor from rat osteosarcoma cells that is 78% identical to the opossum kidney receptor and indicates striking conservation of this receptor across distant mammalian species.
Journal ArticleDOI
Cellular and molecular mechanisms of action of bisphosphonates
Michael J. Rogers,Sharon Gordon,H L Benford,Fraser P. Coxon,S. P. Luckman,Jukka Mönkkönen,Julie C. Frith +6 more
TL;DR: Bisphosphonates currently are the most important class of antiresorptive agents used in the treatment of metabolic bone diseases, including tumor‐associated osteolysis and hypercalcemia, Paget's disease, and osteoporosis.